Patents by Inventor Guangbin Yang

Guangbin Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF
    Publication number: 20230348853
    Abstract: Provided herein are compositions comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and an anti-DOTA C825 antigen binding fragment. The engineered immune cells of the present technology are configured to bind to DOTA haptens that may be complexed with a diagnostic radiopharmaceutical (e.g., 111In). Also disclosed herein are methods for determining the in vivo biodistribution, viability, and expansion of the engineered immune cells described herein.
    Type: Application
    Filed: June 28, 2021
    Publication date: November 2, 2023
    Inventors: Steven Larson, Darren Veach, Sarah Cheal, Ouathek Ouerfelli, Guangbin Yang, Simone Krebs, Megan Dacek, David Scheinberg, Nai-Kong Cheung, Brian Santich
  • SYSTEMS FOR IN VIVO MONITORING OF IMMUNE CELLS IN PATIENTS UNDERGOING CELLULAR IMMUNOTHERAPY
    Publication number: 20230346988
    Abstract: The present disclosure provides kits and methods for tracking or monitoring in vivo biodistribution, viability, and/or expansion of immune cells in a cancer patient undergoing cellular immunotherapy.
    Type: Application
    Filed: June 28, 2021
    Publication date: November 2, 2023
    Inventors: Steven Larson, Darren Veach, Sarah Cheal, Ouathek Ouerfelli, Guangbin Yang, Nai-Kong Cheung, Brian Santich, Simone Krebs, Megan Dacek, David Scheinberg
  • DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY
    Publication number: 20230256121
    Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel compounds that may be complexed with a radioisotope. Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
    Type: Application
    Filed: June 28, 2021
    Publication date: August 17, 2023
    Inventors: Steven Larson, Darren Veach, Sarah Cheal, Ouathek Ouerfelli, Guangbin Yang, Nai-Kong Cheung, Brian Santich, Hong Xu
  • Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
    Patent number: 11565005
    Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: January 31, 2023
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Sarah M. Cheal, Michael McDevitt, Ouathek Ouerfelli, Steven M. Larson, Guangbin Yang
  • N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy
    Patent number: 11413354
    Abstract: The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: August 16, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Ouathek Ouerfelli, Guangbin Yang, Sarah M. Cheal, Steve Larson
  • N-ACETYLGALACTOSAMINO DENDRON-CLEARING AGENT FOR DOTA-PRETARGETED RADIOIMMUNOTHERAPY
    Publication number: 20210330805
    Abstract: The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 28, 2021
    Inventors: Ouathek OUERFELLI, Guangbin YANG, Sarah M. CHEAL, Steve LARSON
  • DOTA COMPOUNDS AND USES THEREOF
    Publication number: 20210188787
    Abstract: Provided herein are DOTA-containing compounds (e.g., compounds of Formula (I)) and complexes that are reactive with an enzyme activator (e.g., a peroxidase) and covalently bind a target analyte (e.g., a protein) in a catalyzed reporter deposition assaying method. The DOTA-containing compounds and complexes are advantageous over existing reporter compounds and complexes because the DOTA moiety allows detection of the reporter moiety by use of mass spectrometry imaging microscopy.
    Type: Application
    Filed: June 13, 2019
    Publication date: June 24, 2021
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Ouathek Ouerfelli, Guangbin Yang, Travis Jason Hollmann
  • DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY
    Publication number: 20210145988
    Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
    Type: Application
    Filed: July 5, 2018
    Publication date: May 20, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Sarah M. CHEAL, Michael MCDEVITT, Ouathek OUERFELLI, Steven M. LARSON, Guangbin YANG
  • Synthesis of thiohydantoins
    Patent number: 9926291
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: March 27, 2018
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • SYNTHESIS OF THIOHYDANTOINS
    Publication number: 20170081308
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • Synthesis of thiohydantoins
    Patent number: 9512103
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: December 6, 2016
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • SYNTHESIS OF THIOHYDANTOINS
    Publication number: 20150191449
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Application
    Filed: March 24, 2015
    Publication date: July 9, 2015
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • Synthesis of thiohydantoins
    Patent number: 8987452
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: March 24, 2015
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • SYNTHESIS OF THIOHYDANTOINS
    Publication number: 20130225821
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Application
    Filed: March 21, 2013
    Publication date: August 29, 2013
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • Synthesis of thiohydantoins
    Patent number: 8461343
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: June 11, 2013
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • MULTIVALENT GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20130095173
    Abstract: Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.
    Type: Application
    Filed: June 10, 2011
    Publication date: April 18, 2013
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Samuel J. Danishefsky, Govind Ragupathi, Philip O. Livingston, Jianglong Zhu, Karthik Iyer, Guangbin Yang
  • SYNTHESIS OF THIOHYDANTOINS
    Publication number: 20100190991
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Application
    Filed: March 27, 2008
    Publication date: July 29, 2010
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao